Efficacy outcomes with InO or SC by leukemic subtype–based risk group. (A) Response to InO was observed across risk groups group based on a classification of leukemic subtypes. In the high-risk BCR::ABL1⁻ group, CR/CRi rates were significantly higher with InO compared with SC. (B) A trend toward a benefit with InO was evident across most risk groups for PFS; (C) OS. ^aCIs were approximated using nominal distribution when ≥5 patients were in both the CR/CRi and non–CR/CRi subgroups. Where <5 patients were in either subgroup, exact method was used. int, intermediate.